The patent game is a losing game – pharma needs to rethink its business model
Unless pharmaceutical companies reinvent the way they offer, create, deliver and capture value, reports such as this that shows AstraZeneca, the UK’s second largest drug maker, suffering a 19% drop in revenues in the last quarter as it was hit hard by the expiry of patents will become more common. A patent holder’s market share can fall by up to 89% in the first half-year following patent expiry.
David Wong
25 October 2012